The TGF-β Pathway as an Emerging Target for Chagas Disease Therapy

dc.creatorAraujo-Jorge, Tania C.
dc.creatorWaghabi, M. C.
dc.creatorBailly, S.
dc.creatorFelge, J. J.
dc.date2017-06-27T13:44:43Z
dc.date2017-06-27T13:44:43Z
dc.date2012
dc.date.accessioned2023-09-26T20:52:13Z
dc.date.available2023-09-26T20:52:13Z
dc.identifierARAÚJO-JORGE, T. C. et al. The TGF-β Pathway as an Emerging Target for Chagas Disease Therapy. Clinical Pharmacology & Therapeutcis, v.92, n.5, p.613-621, Nov. 2012.
dc.identifier0009-9236
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/19522
dc.identifier1532-6535
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8865322
dc.descriptionTransforming growth factor-β (TGF-β) influences the development of myocardiopathy in Chagas disease through regulation of (i) parasite invasion of heart cells, (ii) an intracellular parasite cycle, (iii) inflammation and immune response, (iv) heart fibrosis and remodeling, and (v) gap junction modulation and heart conduction. In this review, we discuss the rationale for developing TGF-β signaling–interfering therapies as adjuvant approaches for the management of the cardiac alterations of Chagas disease-affected patients.
dc.description2030-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherAmerican Society for Clinical Pharmacology and Therapeutics
dc.rightsrestricted access
dc.subjectDoença de Chagas
dc.subjectTratamento
dc.subjectFactor de crescimento de transformação β
dc.subjectCardiomiopatias
dc.subjectChagas Disease
dc.subjectTherapy
dc.subjectTransforming growth factor-β (TGF-β)
dc.subjectmyocardiopathy
dc.titleThe TGF-β Pathway as an Emerging Target for Chagas Disease Therapy
dc.typeArticle


Este ítem pertenece a la siguiente institución